Epicore BioNetworks Inc. Reports Results for Fiscal Year

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Epicore BioNetworks Inc. Reports Results for Fiscal Year 2014

EASTAMPTON, N.J., Oct. 16, 2014 (GLOBE NEWSWIRE) -- Fiscal 2014 was a remarkable year for Epicore (TSX-V: EBN ). Sales records were set in every quarter and net income (without exceptional adjustments) broke the million dollar mark for the first time. Epicore's productivity enhancing products were in high demand as shrimp producers readily accepted new tools and techniques to fight the ravages of Early Mortality Syndrome (EMS) disease. This disease forced closure of some Epicore end customers in fiscal 2013 and hurt Epicore sales but in 2014 decreased shrimp supply pushed shrimp prices to record levels and attracted new usage of our products. Our marketing program increased usage of Epicore products in several new areas. Net income increased by 144% to deliver earnings per share of $0.05.

After a decade of growth, world farm production of shrimp peaked in 2011 at 4.1 million metric tons but declined in 2012 through 2014 to 3.8 million metric tons because of disease problems. The supply shortage caused by EMS has forced shrimp prices to record levels. The effect on Epicore's business has been mixed. When the disease hits farms using Epicore products, it hurts sales. However, higher shrimp prices make Epicore's products more affordable so increase demand for Epicore products from operating farms. High prices encourage farms in affected areas to risk production. In unaffected areas, like South America, India and Indonesia, the high prices encourage farmers to increase production. High prices have decreased shrimp consumption. The Epicore sales team and our distributors responded to this challenge by securing new customers, opening new market areas and exploiting new applications for Epicore products. 

The benefit of the manufacturing expansion started in fiscal 2012 was realized all year in 2014. Our ISO 9001:2008 quality system certification contributed to operational reliability and provided the foundation for our Global GAP initiative. Some highlights (in US$) versus prior fiscal year were:

  • Increase in revenue from $5.6 million to $7.6 million (a 36% increase)
  • Increase in gross profit from $3.5 million to $4.9 million (a 38% increase)
  • Increase in operating expenses from $2.7 to $2.8 million (a 5% increase)
  • Increase in net income from $0.5 million to $1.2 million (a 144% increase)
  • Increase in EBITDA from $0.9 million to $2.1 million (a 133% increase)
  • Increase in shareholders' equity from $5.4 million to $6.7 million (a 24% increase)
  • Increase in cash from $1.9 million to $3.0 million (a 54% increase)
  • Increase in basic and diluted earnings per share from $0.02 to $0.05

Gross profit grew 38% mainly due to the increase in revenues with an improvement in gross margin that was mainly due to lower production costs from the manufacturing expansion of 2013. Operational expenses increased by 5% in fiscal 2014 due to increased selling effort, inflation and spending on research and development. Research and development expenses increased 48% as new research products were scaled up to produce material for field testing.

Epicore generated positive net income of $1.2 million to give Epicore its eleventh consecutive year of profitable operation. Versus prior year, net income increased by $0.7 million (144%). EBITDA, a non-GAAP measure (earnings before interest, taxes, depreciation and amortization), increased 133% over prior year from $0.9 million to $2.1 million, as the following results (rounded to thousands of US dollars) show: 

 
  2014 2013 Increase (Decrease)
Revenue $7,617 $5,613 $2,004 36%
Gross profit $4,879 $3,545 $1,334 38%
Operating expenses $2,847 $2,702 $145 5%
Net income $1,174 $482 $692 144%
Earnings per share $0.05 $0.02 $0.03 150%
Shareholders' equity $6,746 $5,432 $1,314 24%
Cash balance $2,976 $1,939 $1,037 54%

Epicore continues to generate positive cash flows from operating activities with $1.0 million generated in fiscal 2014, which was $0.7 million more than fiscal 2014. Cash at the end of the year was $3.0 million. With these funds, expected sales revenue growth and continued relatively low operating costs, management expects there will be sufficient cash to meet the fiscal year's financial requirements, to fund expansion of aquaculture and environmental remediation marketing efforts and to pursue new strategies for enhancing shareholder value. 

Fiscal 2014 was a successful year not only on a financial basis, but it saw major progress on several operational and strategic issues. The Company actively worked to maintain its ISO 9001:2008 certification and began a program to get HACCP (hazard analysis and critical control point) and Global GAP certification. Many shrimp processing companies have one or more international certifications. Additionally, many government aquaculture product registration authorities are looking for some type of quality certification. 

Fiscal 2014 also saw progress on several corporate issues. 

  • Following TSX Venture Exchange ("TSXV") acceptance, Epicore established a Normal Course Issuer Bid through the facilities of the TSXV. In the year the Company acquired and cancelled 54,000 shares of Epicore common stock. The Company has not renewed the program, which expired on August 28, 2014.
  • The Company participated in a CEO online interview program to increase investor interest. 

The financial statements of the company have been prepared in accordance with International Financial Reporting Standards. Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). [Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.]

This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the company might differ materially from the results, performance or achievements of the company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the future growth of the Company, expected improvements in the quality and reliability of manufacturing operations, acceleration of the Company's penetration into new business areas, the development plans of the company, the expected timing and results of such development and the expectation by management that there will be sufficient cash to meet the fiscal year's financial requirements and to fund expansion of aquaculture and environmental remediation marketing efforts and to pursue new strategies for enhancing shareholder value.   We can provide no assurance that such development will proceed as currently anticipated, that the expected timing or results of such development will be realized or that the company will be able to generate sufficient cash to meet its obligations. We are subject to various risks, including the uncertainties of product development, markets for our products and regulatory review, our need for additional capital to fund our operations, our reliance on collaborative partners, our history of losses, and other risks inherent in the biotechnology industry.

For more information, please contact: Mr. William P. Long (Chief Executive Officer) USA. Tel: 609-267-9118, Email: Investors@EpicoreBioNetworks.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 68

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 186

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 48

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 164

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
Utility Global’s India Steel Move Needs Hard Numbers

Updated Category News Views 38

Steel decarbonization announcements can sound enormous before a single bolt gets tightened. Utility Global says it plans to deploy its first industrial H2Gen project in India with Tata Steel, and that is plainly worth watching. Tata Steel is a serious industrial name, India is a consequential steel market, and any technology that can credibly lower emissions from heavy...

Continue Reading
Humanoid Robots Need Results Before 2035 Hype Peaks

Updated Category News Views 37

A robot climbing stairs is neat; a robot finishing Tuesday’s shift is the investment case. The latest humanoid robotics forecast puts the global market at $3.07 billion in 2026, up from $2.26 billion in 2025, and projects $47.49 billion by 2035. That is a 35.59% compound annual growth rate, the kind of number that makes investors sit up straight. It also demands a...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 71

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading

Top 5 Most Recently Viewed Articles

MPE Partners Invests in SKB Cases to Enhance Growth Potential

Updated Category News Views 369

MPE Partners Makes Strategic Investment in SKB Cases MPE Partners, also known as Morgenthaler Private Equity, has announced an exciting investment in SKB Cases, a prominent manufacturer known for its specialty protective cases. With a robust customer base exceeding 2,000 clients across military, industrial, music, and pro AV sectors, this strategic move is set to...

Continue Reading
Aspire Expands into Europe with EU EMI License and Hub Establishment

Updated Category News Views 186

Aspire Expands into Europe with EU EMI License Aspire, a leading global fintech firm based in Singapore, recently announced a significant breakthrough by acquiring its Electronic Money Institution (EMI) license. This important approval lays the groundwork for its operations in the Netherlands, marking the company's formal entry into the European Union. Milestone for...

Continue Reading
GOTS Combats Greenwashing with Consumer Education Campaign

Updated Category News Views 128

GOTS Takes Action Against Greenwashing The Global Organic Textile Standard (GOTS) is excited to announce the return of its #BehindTheSeams campaign, which aims to raise awareness about the sustainable features of GOTS-certified products. This year's campaign will run throughout September, expanding its efforts to educate consumers about the sustainable practices behind...

Continue Reading
Advancements in Cancer Treatment: Insights from Indaptus Therapeutics

Updated Category News Views 123

Exciting Clinical Developments by Indaptus Therapeutics Indaptus Therapeutics, Inc. (Nasdaq: INDP) is making significant strides in the realm of cancer therapy, focusing on innovative treatments for complex conditions such as urothelial cancer. Their ongoing clinical trial, labeled INDP-D101, has revealed promising results regarding their Decoy20 monotherapy. Recently, a...

Continue Reading
Dr. Réjean Boivin Appointed as Editor-in-Chief of Journal

Updated Category News Views 474

Dr. Réjean Boivin Takes the Helm at Review of Scientific Instruments AIP Publishing is excited to welcome Dr. Réjean Boivin as the new editor-in-chief for Review of Scientific Instruments. Boivin, who previously directed the Center of Excellence for Advanced Diagnostics at General Atomics, is a well-respected figure in the field, having held various roles such as...

Continue Reading